看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
: n7 ~8 h" H% f$ v/ o" N
' Q# L: X3 s, n7 Z* P1 G" e
/ R) K& i$ J& e: Q1 m: Q) DCurrently available feasibility data for possible combination strategies.
# X: |+ r5 t% ?& d* l D6 a————————————————————————————————
. Z' \% D5 x/ m0 L6 \; R# f# x. ]) VCombination Feasibility according to preliminary data
9 e# w6 X# |, W2 o——————————————————————————————————
& ^* S' Y2 K% c, s M4 YBevacizumab + sorafenib Yes, reduced dose ) p+ \) a- m) g0 Q; Z* n, s/ N2 N
Bevacizumab + sunitinib† No ) F; Z/ i! d. N9 a* D+ J
Bevacizumab + temsirolimus Yes
X% \0 P/ C- d0 L. O Q2 YBevacizumab + everolimus Yes ! h t4 Q# c( @& y
Sorafenib + sunitinib ?
2 [% |' D0 t7 \( ~; b6 b$ fSorafenib + temsirolimus Yes, reduced dose ) D9 S5 w2 `' l
Sorafenib + everolimus Yes, reduced dose
; T! E, ~2 {* VSunitinib + temsirolimus† No # o* i" t+ Q. v) e* x! w
Sunitinib + everolimus ?
9 p4 C9 \) C8 A: V Y% M1 RTemsirolimus + everolimus ?
; z7 N% n* k) [. G; I9 |: c————————————————————* ]+ l$ Z+ k, I
†Led to US FDA warning.
/ h# e% h3 u8 ?, t# i- b?: As yet unattempted combination.
, O8 U2 x- c2 d$ X% { |
显身卡
# b) f; r' y0 a' L0 K- d2 K7 Z+ M
